Samsung Bioepis Gains FDA Fast Track for Cancer Drug
The FDA granted Fast Track designation to SBE303, a Nectin-4 antibody-drug conjugate being studied in advanced urothelial cancer.
Updated on Nov. 17, 2026 in Cancer

Samsung Bioepis received FDA Fast Track designation for SBE303, its first novel antibody-drug conjugate, which targets Nectin-4 in adults with locally advanced or metastatic urothelial cancer previously treated with enfortumab vedotin. The designation allows more frequent interaction with the FDA and could lead to a faster review.
Why it matters
Existing Nectin-4 antibody-drug conjugates can be limited by a narrow therapeutic index and side effects that restrict dosing. The designation reflects the critical unmet medical need in patients with advanced solid tumors.
SBE303 is in phase 1 trial NCT07524348, with no efficacy results yet disclosed for the antibody-drug conjugate. Its related SB27 biosimilar showed a 34.6% objective response rate at week 24 against 37.9% for Keytruda, within the predefined equivalence margin, though whether SBE303 will reach similar outcomes remains unknown.
The players
Samsung Bioepis
Samsung Bioepis is the biopharmaceutical arm of the Samsung group that develops biosimilar and novel therapeutics, including antibody-drug conjugates and biosimilars of major cancer immunotherapies.
The details
SBE303 pairs a highly specific antibody against Nectin-4 with a topoisomerase I inhibitor payload joined by the company's own linker technology. The drug is in phase 1 trial NCT07524348 for patients with urothelial cancer.
Timeline
October: FDA granted Fast Track designation to SBE303.
Next year: Samsung Bioepis expects to present final progression-free and overall survival results for SB27, with full manuscript publication expected.
Market Landscape
Samsung Bioepis is extending its Keytruda biosimilar work, with the SB27 interim phase 3 response rate of 34.6% against Keytruda's 37.9% placing the company in direct competition with the original immunotherapy. Adding SBE303 signals a move from biosimilars into novel antibody-drug conjugates, a segment where Nectin-4 agents are already being developed by other drugmakers.
For patients with advanced urothelial cancer, a Fast Track designation can mean more frequent regulatory contact and a potentially faster path to review, though no treatment is approved yet. Patients should discuss any emerging options with their oncologist, as trial eligibility for SBE303 is limited to adults previously treated with enfortumab vedotin.
The takeaway
Fast Track designation accelerates communication with regulators but does not confirm efficacy, so readers should watch for phase 1 results before drawing conclusions about SBE303's benefit.
What happens next
Samsung Bioepis expects to present final progression-free and overall survival results for SB27 next year, with data from patients continuing treatment for up to 100 weeks to be reported separately.
Further reading
Explore more on Cancer treatments and drug development.
Source note: This article includes information reported by Managedhealthcareexecutive.



